Acute Bacterial Skin and Skin Structure Infections (ABSSSI ) Market Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Acute Bacterial Skin and Skin Structure Infections (ABSSSI ) Market
Acute bacterial skin and skin
structure infections (ABSSSI) are a group of infections caused by bacteria that
affect the skin and surrounding tissues. These infections can be caused by a
variety of bacteria, including Staphylococcus aureus and Streptococcus
pyogenes, and can range in severity from mild to life-threatening. ABSSSI can
present as cellulitis, erysipelas, or infected wounds.
The market for ABSSSI treatments
has been growing rapidly in recent years, driven by an increase in the
prevalence of antibiotic-resistant bacteria and the development of new and
effective treatments for these infections.
Market Overview
The Acute
Bacterial Skin and Skin Structure Infections Market was valued
at approximately $5.4 billion in 2020 and is expected to grow at a compound
annual growth rate (CAGR) of 5.8% from 2021 to 2028. The market is driven by
factors such as the increasing prevalence of ABSSSI, rising healthcare
expenditure, and the development of new and effective treatments.
The Acute
Bacterial Skin and Skin Structure Infections Market is segmented
by treatment type, including antibiotics, immunoglobulins, and others.
Antibiotics are the most commonly used treatment for ABSSSI, and this segment
accounted for the largest market share in 2020. Within the antibiotics segment,
the cephalosporin class of antibiotics is the most commonly prescribed.
Geographically, North America
dominates the Acute
Bacterial Skin and Skin Structure Infections Market, followed by
Europe and the Asia Pacific. The high prevalence of ABSSSI in North America,
along with the presence of major market players in the region, is driving the
growth of the market in this region.
Key Market Players
The Acute
Bacterial Skin and Skin Structure Infections Market is highly
competitive, with several major players vying for market share. Some of the key
market players include:
Merck & Co., Inc. - Merck
& Co., Inc. is a global pharmaceutical company that develops and markets
drugs for a wide range of diseases, including ABSSSI. The company's flagship
product for ABSSSI is Zerbaxa, a combination antibiotic that has been approved
for the treatment of complicated intra-abdominal infections and ABSSSI.
Pfizer Inc. - Pfizer Inc. is a
global pharmaceutical company that develops and markets drugs for a wide range
of diseases, including ABSSSI. The company's flagship product for ABSSSI is
Dalvance, a second-generation lipoglycopeptide antibiotic that has been
approved for the treatment of ABSSSI.
Tags: healthcare, Healthcare
Industry, Pharmaceutical, Acute Bacterial Skin and Skin
Structure Infections, Acute Bacterial Skin and Skin Structure Infections Market
Comments
Post a Comment